1	Not received an unlicensed investigational agent drug device or blood-derived product within 30 days prior to randomization and may not receive such an investigational agent in the 30 days post-randomization note investigational use for treatment of TMA of a licensed immunomodulator e.g. rituximab|TMA[250,253]|||||||30 days[93,100]|||89775|89775|tma
1	Not received an unlicensed investigational agent drug device or blood-derived product within 30 days prior to randomization and may not receive such an investigational agent in the 30 days post-randomization note investigational use for treatment of TMA of a licensed immunomodulator e.g. rituximab|TMA[93,100]||||||||||89775|89775|tma
1	Not received an unlicensed investigational agent drug device or blood-derived product within 30 days prior to randomization and may not receive such an investigational agent in the 30 days post-randomization note investigational use for treatment of TMA of a licensed immunomodulator e.g. rituximab|immunomodulator[268,283]||||||||||491496|491496|immunomodulator
1	Not received an unlicensed investigational agent drug device or blood-derived product within 30 days prior to randomization and may not receive such an investigational agent in the 30 days post-randomization note investigational use for treatment of TMA of a licensed immunomodulator e.g. rituximab|rituximab[289,298]|||||||||C0393022|121191|121191|rituximab
